News

Prime Minister Benjamin Netanyahu with Mr. Ronen Gadot, CEO of ElMindA

Israeli delegation members

This week, Prime Minister Benjamin Netanyahu visited China and was accompanied by a senior business delegation of dozens of Israeli businesspeople from the various industries and companies active in China, as well as from companies interested in penetrating the Chinese market. Delegation members attended a business forum with over 500 invited guests, that was chaired by the Prime Minister. Among the companies that were carefully selected to showcase Israel’s most transformational innovations was ElMindA.

 The visit followed an invitation by Chinese President Xi Jinping and marked 25 years since the establishment of diplomatic relations between the two countries. During this visit, Israel and China signed cooperation agreements in aviation, education, bringing Chinese construction workers to Israel, science, health, environmental protection and a multi-year plan for a task force on strengthening bilateral economic ties

 “We will continue the talks on establishing a free trade agreement between China and Israel and we will hold the third joint Israel-China innovation conference. Of course, we are continuing to develop new markets and to open new markets for the Israeli economy. I expect all ministers to cooperate on this, and they are doing so”, said Mr. Netanyahu.

ANVISA Certification

ElMindA, a World Economic Forum technology pioneer, and EMOTIV, run by Tan Le, a World Economic Forum Young Global Leader, are among the companies working to make it happen. Read more on World Economic Forum.

Read more on Business Wire and Yahoo

 

Link to video: USA Today

BNA™ (Brain Network Activation) provides detailed knowledge of brain function over time. Potential to impact an estimated 2 billion people worldwide living with neurological, psychiatric disorders.

CHICAGO, November 16, 2015 – ElMindA Ltd., a pioneer in neuroscience-based technology for analyzing brain network functionality, today announced the successful completion of an oversubscribed $28 million Series C financing round. The global syndicate of investors in this round includes Shanda Group, New England Patriots owner – The Kraft Group, Wexford Capital, WR Hambrecht & Co, Palisade Capital Management, OurCrowd and Healthcrest AG and others. Proceeds will be used to continue advancement of ElMindA’s proprietary BNA™ (Brain Network Activation) system, which uses multi-channel EEG-ERP electrophysiology technology to provide a more accurate, objective assessment of brain functionality over time. ElMindA will also use the funds for commercial and clinical adoption following BNA’s 2014 FDA clearance in the U.S., and CE Mark approval in Europe for brain function assessment.

“We are thrilled to have attracted such a strong group of new and existing investors,” said Ronen Gadot, chief executive officer of ElMindA. “This support is a testament to the vast potential of BNA technology to advance our understanding of how the brain works, and to positively impact people’s lives. We plan to bring BNA to the forefront as a significant resource to monitor and manage the health of your brain throughout the course of your life.”

“As an investor who has followed the advancements of the company for several years, we look forward to supporting ElMindA as it further unlocks the potential of BNA to be the preeminent market leader by offering an objective platform for brain function assessment and management of brain disorders,” said Robert Kraft of the Kraft Group.

BNA is a non-invasive technology for measuring and analyzing brain function. It uses advanced signal processing and machine-learning algorithms of big populations’ data in order to identify patterns of neuronal networks activated during a specific brain function, such as memory or attention. The information can then be utilized for personalized clinical decision making. It has the potential to impact an estimated two billion people worldwide living with neurological and psychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, depression, and ADHD, as well as those who have sustained traumatic brain injuries, like concussion. BNA is responsive to the BRAIN Initiative announced by the White House, which focuses on revolutionizing our understanding of human brain function through the development and application of innovative technologies.

 

“ElMindA has developed a truly disruptive technology that addresses a crucial unmet need,” said Tianqiao Chen of Shanda Group. “We’re excited to help develop and promote such a unique technology that can potentially catalyze new treatment options for those affected by brain dysfunction.”

“BNA’s exploration of brain function has already affected the lives of young people and their physicians in the U.S. seeking additional guidance for critical brain health decisions,” said Bill Hambrecht of WR Hambrecht & Co. “It has the potential to be of value to each and every one of us in our lifetime.”

BNA is currently available to healthcare providers at 15 locations in eight U.S. cities, including Chicago, Los Angeles, Philadelphia, Minneapolis, Phoenix, Ann Arbor, Hartford, and Palm Beach.

About BNA™

BNA™ is a breakthrough technology to monitor and manage the health of your brain throughout the course of your life. It combines non-invasive, multi-channel EEG technology with sophisticated signal processing and analysis algorithms to measure patterns of brain networks activated during specific brain processes to deliver meaningful insights into brain functionality. In addition to concussion, use of BNA is being explored as a tool for physicians to monitor change in brain networks to help identify disease onset and assess treatment efficacy for a broad range of previously elusive conditions such as depression, pain, or memory loss. The BNA Analysis System is to be used by qualified medical professionals for the post-hoc analysis of the human Electroencephalogram (EEG), utilizing evoked response potentials (ERP). The device is indicated in the U.S. for use in individuals 14 to 24 years of age with the Auditory Oddball task only. For more information about BNA visit, www.ElMindA.com.

 About ElMindA Ltd.  

ElMindA was founded in 2006 by Professor Amir Geva to address an unmet need to objectively assess brain health and brain-related disorders in order to enhance diagnosis and treatment across a full spectrum of neurological and psychological disorders. ElMindA translates state-of-the-art neuroscience via advanced algorithmic science into clinically meaningful Brain Network Activation (BNA™) maps. ElMindA is a preferred partner of industry-leading organizations based on the rigor of its science and technology development. ElMindA was recognized on Fast Company’s 2015 list of the World’s Most Innovative Companies, and was named a 2015 World Economic Forum Technology Pioneer.

 

In honor of the famous neurologist’s life, GEEKTIME has compiled a list of five of the most innovative brain tech companies and projects operating today. read more.

geektime-logo1

ElMindA has been honored among a select group of global innovators named to the World Economic Forum’s Technology Pioneers for 2015. The World Economic Forum’s Technology Pioneers program recognizes companies from around the world that are involved in the design, development and deployment of new technologies, and are poised to have a significant impact on business and society. Read more on Yahoo finance,   ISRAEL21c and WEF press release.  Read WEF interview with CEO Ronen Gadot.

World Economic Forum Technology  Pioneers 2015

A study published by Brain Imaging and Behavior provides important new information about the assessment of patients following a concussion, particularly those with post-traumatic migraine (PTM). The study compared individuals with PTM following sport-related concussion (SRC) to those without PTM following SRC, as well as healthy individuals, utilizing Brain Network Activation (BNA™). The findings indicate that individuals with PTM following sports-related concussion exhibit reduced BNA network activity and connectivity scores, and support use of BNA in assessing PTM throughout post-concussion recovery. The full study can be accessed  here.

Athletico, a leader in head injury and concussion management, announced the availability of BNA™ testing at its Chicago-area facilities. Learn more here and review the article on the Daily Herald.

Herzliya – ElMindA Ltd. announced today that the Israeli Ministry of Health has approved registration of the company’s BNA™ Analysis System as a medical device for the assessment of brain function. Brain Network Activity (BNA™) combines non-invasive, multi-channel EEG technology with sophisticated signal processing and analysis algorithms to measure patterns of brain networks activated during specific brain processes and deliver both quantitative and qualitative insights into brain functionality. The BNA™ output allows healthcare providers to assess a patient’s functional brain network activity and compare it with functional network activity of healthy brains. BNA™ is currently cleared for 14 to 24 year-olds, and the company is conducting additional research activities to further expand the indicated age group.

ElMindA, creator of the ground-breaking Brain Network Activation (BNA™) technology has been recognized once again for its innovative approach to neuroscience and management of brain disorders. The company was included on Fast Company’s annual list of the World’s Most Innovative Companies that ranks the top 50 companies that are radically changing an industry, consumer habits and assumptions. Not only was ElMindA honored on the Top 50 Worldwide list, but it also placed within the Top 10 Most Innovative companies in the Healthcare and Israel categories.
In August 2014, ElMindA announced that BNA™ was cleared by the U.S. Food and Drug Administration (FDA) for the analysis of brain functional network activity, initially indicated for 14 to 24 year olds. ElMindA research showed, for the first time, the ability of BNA to map pain pathways in the brain and objectively and sensitively differentiate between a drug effect and a placebo effect on the brain – previously only possible by subjective measures.
The full list of companies is in the March 2015 issue of Fast Company, and more information can be found here.

MorningstarLogo-Headerelectrical-geodesics

LONDON (Alliance  News) – Electrical Geodesics Inc on Thursday said it has signed a two-year deal with ElMindA to provide its GES 400 systems to the US-Israeli company’s Brain Network Activation platform.

The BNA platform is an analysis system which received clearance from the US Food and Drug Administration last year for the assessment of brain function in 14-to-24-year-olds.

Under the deal, Electrical Geodesics will supply and support customers of ElMindA who buy the BNA analysis system with its GES 400 dense array EEG systems on pre-determined terms. It did not provide financial details of the deal.

“We have worked with ElMindA over a number of years and are pleased that their research efforts have led to the BNA system receiving FDA clearance. ElMindA recognises the need for the precision dense array EEG provides to enable objective assessment of brain disorders and injuries,” said Electrical Geodesics Chief Executive Officer Don Tucker.

See more on Morningstar

BNA™ on IBA News

December 22nd, 2014

Watch IBA News story on BNA™ broadcast on November 26th 2014

 

 

BNA™ FDA clearance in the news:

MDBR Medical Device Business Review, August 5th, 2014

ElMindA obtains FDA approval for BNA Analysis System

Globes, August 6th, 2014

ElMindA receives FDA approval for brain-scanner

Times of Israel, August 13th, 2014

What’s on your mind? ElMindA’s ‘helmet’ knows

Israel 21C, August 14th, 2014

FDA clears ElMindA for BrainAnalysis

Jewish Business News, August 26th, 2014

ElMindA Brain Scan Helmet Gets FDA Approval

 

BNA™ on Yahoo Sports

August 27th, 2014

ANN ARBOR, Michigan; “Concussion test that feels like ‘octopus giving your head a hug’ could greatly benefit NFL players, other athletes”. Read the full story on BNATM

 

Advanced brain analysis and mapping technology enables assessment of brain health based on objective neurophysiological measures

FDA LOGO

CHICAGO, Aug. 4, 2014 – ElMindA Ltd. announced today that the United States Food and Drug Administration (FDA) has cleared the company’s BNA™ Analysis System for the assessment of brain function. Brain Network Activity (BNA™) combines non-invasive, multi-channel EEG technology with sophisticated signal processing and analysis algorithms to measure patterns of brain networks activated during specific brain processes and deliver both quantitative and qualitative insights into brain functionality. The BNA™ output allows healthcare providers to assess a patient’s functional brain network activity and compare it with functional network activity of healthy brains. BNA™ is currently cleared for 14 to 24 year-olds, and the company is conducting additional research activities to further expand the indicated age group.

“Greater understanding of how our brain processes information, how it gets its job done, ultimately holds the potential to improve brain health and disease management over a person’s lifetime,” said Ronen Gadot, CEO of ElMindA. “BNA™ adds an objective layer of information to clinical symptom assessments and neurocognitive tests, providing clinicians with a comprehensive view of brain health.”

“BNA™ allows physicians to assess brain health using objective neurological measurements,” said Jeffrey S. Kutcher, M.D., associate professor of neurology, University of Michigan Medical School. “This will allow those of us caring for patients the ability to more clearly differentiate a healthy brain from one affected by disease or injury, and potentially have more informed discussions about lifestyle, activity, prevention and treatment decisions as a result.”

ElMindA has established a growing database of brain activity from both healthy subjects and patients with brain-related disorders. The database currently includes more than 7,000 BNA™ datasets, which provide a robust, clinically supported foundation to potentially help identify and manage neurological disorders such as ADHD or pain, and brain injuries such as concussion. Prominent clinical institutions across the country are leading research studies focused on the use of BNA™ across several of these areas.

About ElMindA Ltd.

Founded in 2006 to address an unmet need in the accurate, objective diagnosis and treatment of brain-related disorders, ElMindA is pioneering brain assessment technologies designed to inform critical decisions by providing a clear view of brain function over time. The company uses a data-driven approach to transform algorithmic science and neuroscience expertise into routine clinical practice, and is a preferred partner of industry-leading organizations based on the rigor of its science and technology development.

BNA™ FDA clearance on the news:

MDBR Medical Devise Business Review, August 5th 2014

ElMindA obtains FDA approval for BNA Analysis System

Globes, Agust 6th 2014

ElMindA receives FDA approval for brain-scanner

Times of Israel, August 13th 2014

What’s on your mind? ElMindA’s ‘helmet’ knows

Israel 21C, August 14th 2014

FDA cleares ElMindA for BrainAnalysis

Jewish Business News, August 26th 2014

ElMindA Brain Scan Helmet Gets FDA Approval

Media Contacts:

Krystle Gibbs

617.761.6702

krystle.gibbs@fkhealth.com

Watch the  Télématin FR2  story on BNA™ broadcast on June 17th 2014.

ElMindA has received a certification for  EN ISO 13485:2012 and CMDCAS  ISO 13485:2003, an international standard for a company-wide quality management system.

EN ISO 13485:2012 certificate (Valid to March 2017)

ISO 13485:2003 under CMDCAS certificate (Valid to March 2017)

Pittsburgh March 12th 2014

UPMC, Israeli company partner on brain-mapping work. A collaboration between the Israeli company ElMindA, and the UPMC Sports Medicine Concussion Program, has generated research results that could lead to better concussion assessments and more effective treatments. Read the full story on BNA™.

BNA™ on CBS Minnesota news

November 21st, 2013

MINNEAPOLIS (WCCO) — This fall, 150 Minnesota youth hockey players are taking part in a study that’s using BNATM, a new concussion test to measure brainwaves. The studies’ directors believe the test could someday give parents an immediate diagnosis and peace of mind. Watch the CBS Minnesota story on BNATM.

 

Elminda_logo_sPurdueLogo

ElMindA and Purdue Pharma L.P. Enter Research Agreement to Develop Novel Diagnostics to Improve Pain Management

 

Collaboration Extends Use of ElMindA BNA™ Technology Research

Herzliya, Israel and Stamford, Conn. USA – January 29, 2013 – ElMindA – the developer of an innovative technology capable of providing drug developers with superior insights into the effect of therapeutic interventions on brain function – has entered into a strategic, multi-year research collaboration agreement with Purdue Pharma L.P., a leading developer of pharmacologic therapies to treat and manage pain.

The staged research collaboration will focus on pain diagnosis and management, through the development of objective assessments of analgesia as well as other subjective responses to treatment, and include several projects aimed at the discovery and development of new clinical diagnostic tests and biomarkers to manage pain and to enable the development of more effective pain treatments.

“We are extremely pleased to enter into this collaboration with Purdue Pharma that will apply our advanced Brain Networks Activation (BNA™) technology to research efforts for the development of better diagnostic tools and biomarkers for pain management,” said Ronen Gadot, CEO of ElMindA. “Partnering with Purdue Pharma is another significant step forward for ElMindA, marking an expansion of the company’s collaborations with pharma companies and the addition of pain management to the Company’s portfolio of therapeutic focus.”

ElMindA’s BNA™ technology combines the most advanced brain imaging tools with ElMindA’s proprietary algorithms and signal processing to produce unparalleled detail and precision of brain functional mapping.  In the area of drug development, the BNA™ technology can shed light on the dynamic functional changes in brain networks pre- and post-drug administration to reveal mechanisms of action, optimize drug dosages and identify responders and non-responders to therapies early in the drug development process.

As part of an expanding R&D innovation strategy, Purdue is broadening the scope of its research collaborations beyond drug discovery and development in order to identify opportunities that can enhance the overall quality of pain management. Purdue scientists are evaluating potential mapping systems to objectively assess pain, new applications and technologies for pain management, new technologies for controlling drug release, and methods to assess treatment compliance.

“We are very excited about this collaboration and look forward to leveraging ElMindA’s BNA™ technology in a combined effort to enhance the diagnosis, treatment and management of pain. This collaboration is another important effort towards advancing care for pain patients and further demonstrates Purdue’s commitment as a leader in the field of pain management,” said Dr. Craig Landau, Chief Medical Officer for Purdue.

Clinical diagnostic tests to improve pain management and biomarkers for drug development resulting from the collaboration will be used and commercialized by ElMindA and/or Purdue.

About ElMindA:  ElMindA was founded in 2006 with the vision of revolutionizing the management of brain disorders and injuries by transforming state-of-the-art neuroscience into bed-side clinical practice, opening a new window into functionality of the brain.  The company seeks to dramatically improve clinical decision-making for Central Nervous System (CNS) disease management through wide utilization of its BNA™ testing as an objective measurement of brain function, dysfunction, disease progression and recovery. The ElMindA BNA™ technology is currently being used for drug development research with leading pharmaceutical companies and in research with prominent academic research centers throughout the U.S. and Europe.   In 2012,ElMindA submitted the technology for FDA clearance. The technology is not currently cleared for clinical use.

About Purdue Pharma L.P:  Purdue Pharma and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain. Headquartered in Stamford, CT, Purdue Pharma is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicine and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

 

#   #   #

 Contact:

For Purdue Pharma L.P.

James Heins

Senior Director, Public Affairs

Purdue Pharma L.P.

Tel: 203-588-8069

Mobile:  203-856-2121

Email:   james.heins@pharma.com

 

For ElMindA:

Nicholas Weber
Vice President
FaegreBD Consulting
Tel: 317-237-1312

Email:   nicholas.weber@FaegreBD.com

The Wonders of our Mind

Neuroscience

 Receiving a Transmission from the Brain

ElMindA is developing a tool that measures our brain’s electrical fields and signals during brain activity, in order to enable brain-disorder diagnosis and treatment in real time

 

One  of  the  most  important  discoveries  in  neuroscience  –  perhaps  the  final  frontier  for  medical science  specifically  and  for  science  in  general  –  is  the  degree  to  which  the  brain  works  as  a synchronized,  organized  system  rather  than  as  isolated  regions.  Another  no  less  important discovery is that the brain is largely flexible and plastic, a fact that gives much hope in regard to its healing abilities. And  yet, compared to most fields of modern medicine, such as cardiology, orthopedics  and  gynecology,  in  which  diagnosis,  treatment  and  follow-up  all  rely  on  precise measuring equipment (ultrasound, CT, etc.), the fields of medicine dealing with the brain – such as psychiatry and neurology – are forced to operate under vague, uncertain conditions in terms of the quality of diagnosis and the efficacy of care.

What  is  it:  The  goal  of  the  research  conducted  by  Professor  Amir  Geva  over  the  last  thirty years, and by the ElMindA Corporation, over the last six years, was to bring modern medicine to the brain by developing an imaging and treatment tool that would enable measuring and tracking of  the  network  activities  of  high  neural  processes  such  as  memory  and  identification,  clear presentation  of  the  information  to  the  attending  physician  and,  when  necessary,  repairing  and improvement  of  neural  network  processes  using  external  or  internal  stimulus  adjusted  to measurement. This may improve the lives of one third of the world’s population who suffer from various brain-related illnesses. 

It has been known for some time that the brain is composed of complex networks of neurons that work  together  in  time  and  space  to  perform  complex  tasks,  such  as  processing  and  identifying sensory  input,  long-  and  short-term  memory  storage,  attention,  and  abstract  thinking,  but  it  is very difficult to measure this activity.

How does it work: The company’s technology is based on measuring the electrical fields that are created through the brain’s neural electrical activity on the scalp and around the head during the performance of various cognitive tasks, and then reevaluating the relevant active neural network in  terms  of  time  and  location  in  the  brain,  using  advanced  methods  of  signal  processing  and pattern recognition taken from engineering and computer science research.

The  brain  behind  it:  Professor  Geva,  together  with  Goded  Shahaf  and  Ronen  Gadot,  set  up ElMinda  in  2006,  with  the  purpose  of  measuring  network  activities  of  the  functional  and dysfunctional  human  brain  during  performance  of  various  cognitive  tasks,  to  enable  diagnosis and treatment of brain disorders while tracking changes in the network activity accordingly.

Status:  The  company  is  currently  involved  in  various  stages  of  the  complex  and  expensive process of developing drugs with leading teams from the largest pharmaceutical corporations in the world. The goal of this process is to measure and understand the effects of the drugs on the human brain’s network activities, and thus to develop new and effective drugs whose effects on the  human  brain  are  known  and  measured  and  which  could  be  used  to  treat  disorders  such  as Parkinson’s,  Alzheimer’s,  ADHD,  schizophrenia,  pain,  depression  and  more.  The  company  is concurrently  working  to  develop  a  system  for  the  diagnosis  and  the  post-treatment  clinical follow-up  of  various  brain  disorders  and  illnesses,  including  ADHD,  concussions,  pain, rehabilitation after stroke, and more: this will enable correct decisions to be made based on direct measurement of the activity in the organ being treated – the brain.

Introducing a novel approach of network oriented analysis of ERPs, demonstrated on adult attention deficit hyperactivity disorder; G. Shahaf, A. Reches, N. Pinchuk, T. Fisher G. Ben Bashat, A. Kanter, I. Tauber, D. Kerem, I. Laufer, J. Aharon-Peretz, H. Pratt, A.B. Geva.

http://www.ncbi.nlm.nih.gov/pubmed/22261156

Back to top